After scoring an early authorization for its COVID-19 therapy remdesivir, Gilead Sciences has been on the hunt for manufacturing partners to help boost production for the in-demand drug. Through a series of licensing agreements, Gilead has taken the first steps
read moreNearly four years removed from a disastrous sales fraud probe and an overhaul of its senior leadership, Alexion has launched a dealmaking campaign to bolster its rare disease pipeline. But one activist investor thinks Alexion’s strategy is ill-conceived—and the old foe
read moreWith eight COVID-19 vaccines in human testing and headlines touting their progress each day, a leading U.S. health official voiced some optimism about one or more of them working. More: With 'multiple shots on goal,' NIAID director Anthony Fauci is ‘cautiously optimistic’ about
read moreBeiGene is squaring off against industry bigwigs with its new BTK inhibitor Brukinsa, and early sales figures show just how difficult it will be for the Chinese biotech to steal share in the U.S. market. Luckily for the company’s first-quarter
read moreWith its megamerger with Allergan finally in the books, AbbVie is officially a colossus with a bustling drug portfolio and a few strategic hurdles in its immediate future. But the new AbbVie will be stronger than ever, one analyst argues—and investors
read moreAround half of England’s population is now served by an ICS More: NHS England confirms four new ICSs Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals